March 4, 2024

Xanomeline‐trospium combination shows strong results in schizophrenia trial

Key Points

Key points are not available for this paper at this time.

Abstract

A drug that combines the muscarinic receptor agonist xanomeline and the muscarinic receptor antagonist trospium reduced positive and negative symptoms of schizophrenia in a Phase 3 placebo‐controlled trial. The study's investigators wrote that the results suggest the drug, known as KarXT, could represent a new class of antipsychotic medications. Results were published online Dec. 14, 2023, in The Lancet.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Cite this study

A Mon, study studied this question.

synapsesocial.com/papers/68e75dc8b6db6435876d4963 — DOI: https://doi.org/10.1002/pu.31139

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Second Phase 3 trial shows benefit of xanomeline‐trospium in schizophrenia· 2024
Efficacy and Safety of Xanomeline-Trospium Chloride in Schizophrenia· 2024 · 156 citations
KarXT: Combination of Xanomeline and Trospium· 2024 · 1 citations
Trial shows safety of switch to xanomeline‐trospium combination in stable patients· 2026
Efficacy of Xanomeline-Trospium (KarXT) in Reducing Schizophrenia Symptoms: A Systematic Review and Meta-Analysis of Randomized Controlled Trials· 2025 · 1 citations

Xanomeline‐trospium combination shows strong results in schizophrenia trial

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Cite this study

Also consider

Journals

Actions

References and Citations

Citation Network

Connected Papers

Discussion

Also consider